NCT01214291WithdrawnPhase 3
Phase III Randomized, Double-Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate 80 mg for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer on Androgen Deprivation Therapy
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Withdrawn
- Sponsor
- GTx
- Locations
- 1
- Primary Endpoint
- To confirm the efficacy of toremifene 80mg compared with placebo in the reduction in the risk of new bone fracture occurrences in men with prostate cancer on androgen deprivation therapy as measured by semiquantitative assessment of vertebral fractures
Study Overview
Brief Summary
The purpose of this study is to determine whether Toremifene Citrate is effective in reducing the risk of bone fractures in men with prostate cancer who are on Androgen Deprivation Therapy.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Triple (Participant, Care Provider, Investigator)
Eligibility Criteria
- Ages
- 50 Years to 80 Years (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •give voluntary signed informed consent
- •have histologically documented prostate cancer
- •have been on ADT treatment for 6 months prior to randomization or intermittent LHRHa for preceeding 12 months
- •expected to continue LHRHa therapy uninterrupted for the next 12 months
- •have total testosterone levels less than 50 ng/dL
- •Have BMD of lumbar spine or femoral neck at or below the BMD thresholds
- •have a Zubrod performance status <or equal to 1
- •subject weight <300 lbs(<136 kg)
- •agree to complete a daily diary of medication intake
- •agree not to take excluded medications throughout the trial
- •agree to use an effective method of contraception
- •have adequate bone marrow, liver and renal functions
Exclusion Criteria
- •Currently or previously exposed
- •within the past 5 years to intravenous bisphosphonates, strontium ranelate or Denosumab
- •for more than 3 years to oral bisphosphonates
- •within the last 45 days to PTH or PTH derivative, anabolic steroids or testosterone, SERMs, calcitonin, calcitriol or oral gluccorticoids
- •have any disease or condition that would preclude an accurate evaluation of radiographs of the thoracic or lumbar spine
- •have <8 evaluable vertebrae
- •have a BMD T score <-4 at the lumbar spine or total hip or femoral neck
- •have any history of other carcinomas within the last 5 years
- •Serum PSA > 5ng/mL at baseline under ADT
- •have Paget's disease, Cushing's disease, chronic hepatitis or cirrhosis or rheumatoid arthritis
- •have active uncontrolled systemic viral, bacterial or fungal infections
- •have a clinically significant concurrent illness or psychological, familial, sociological, geograhical or other condition that would not permit adequate follow-up and compliance
- •received treatment with other investigational agents within 30 days
- •taking finasteride, dutasteride, danazol or testosterone like substances
- •taking herbal medicines or dietary supplements
- •have a history of thromboembolic disease including DVT or pulmonary embolus
- •have a QTcF of > or equal to 450 msec or congenital or acquired QTc prolongation
- •calcicum urolithiasis prohibiting the use of vitamin D
Outcomes
Primary Outcomes
To confirm the efficacy of toremifene 80mg compared with placebo in the reduction in the risk of new bone fracture occurrences in men with prostate cancer on androgen deprivation therapy as measured by semiquantitative assessment of vertebral fractures
Time Frame: 36 months
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)Preneoplastic ConditionsProstatic Intraepithelial NeoplasiaNCT00106691GTx1,589
Active, not recruiting
Phase 3
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)Atherosclerotic Cardiovascular Disease (ASCVD)Chronic Kidney Disease (CKD)NCT06383390Eli Lilly and Company10,000
Completed
Phase 2
Topiramate for Alcohol and Cocaine DependenceCocaine DependenceAlcoholismNCT00167245Kyle Kampman170
Active, not recruiting
Phase 3
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 MutationAmyotrophic Lateral Sclerosis Associated With a SOD1 Gene MutationNCT04856982Biogen158
Active, not recruiting
Phase 3
Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-upCarcinoma, Intraductal, NoninfiltratingRecurrence, Local NeoplasmBreast NeoplasmsAtypical HyperplasiaNCT01357772Andrea DeCensi500